Opus Genetics (IRD) Competitors $0.98 -0.04 (-4.25%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$0.96 -0.01 (-1.19%) As of 06/27/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock IRD vs. TVGN, BTMD, INBX, DSGN, ESPR, NBTX, MDWD, CRDF, IMAB, and PRQRShould you be buying Opus Genetics stock or one of its competitors? The main competitors of Opus Genetics include Semper Paratus Acquisition (TVGN), biote (BTMD), Inhibrx Biosciences (INBX), Design Therapeutics (DSGN), Esperion Therapeutics (ESPR), Nanobiotix (NBTX), MediWound (MDWD), Cardiff Oncology (CRDF), I-Mab (IMAB), and ProQR Therapeutics (PRQR). These companies are all part of the "pharmaceutical products" industry. Opus Genetics vs. Its Competitors Semper Paratus Acquisition biote Inhibrx Biosciences Design Therapeutics Esperion Therapeutics Nanobiotix MediWound Cardiff Oncology I-Mab ProQR Therapeutics Opus Genetics (NASDAQ:IRD) and Semper Paratus Acquisition (NASDAQ:TVGN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk. Do institutionals & insiders hold more shares of IRD or TVGN? 15.0% of Opus Genetics shares are owned by institutional investors. 6.6% of Opus Genetics shares are owned by company insiders. Comparatively, 73.2% of Semper Paratus Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Do analysts recommend IRD or TVGN? Opus Genetics presently has a consensus target price of $7.33, suggesting a potential upside of 650.90%. Semper Paratus Acquisition has a consensus target price of $10.00, suggesting a potential upside of 706.45%. Given Semper Paratus Acquisition's higher possible upside, analysts clearly believe Semper Paratus Acquisition is more favorable than Opus Genetics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Opus Genetics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Semper Paratus Acquisition 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable earnings and valuation, IRD or TVGN? Semper Paratus Acquisition has lower revenue, but higher earnings than Opus Genetics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOpus Genetics$10.99M5.30-$57.53M-$2.10-0.47Semper Paratus AcquisitionN/AN/A-$13.73MN/AN/A Does the media favor IRD or TVGN? In the previous week, Opus Genetics had 7 more articles in the media than Semper Paratus Acquisition. MarketBeat recorded 8 mentions for Opus Genetics and 1 mentions for Semper Paratus Acquisition. Semper Paratus Acquisition's average media sentiment score of 1.89 beat Opus Genetics' score of 0.28 indicating that Semper Paratus Acquisition is being referred to more favorably in the news media. Company Overall Sentiment Opus Genetics Neutral Semper Paratus Acquisition Very Positive Is IRD or TVGN more profitable? Semper Paratus Acquisition has a net margin of 0.00% compared to Opus Genetics' net margin of -429.42%. Semper Paratus Acquisition's return on equity of 0.00% beat Opus Genetics' return on equity.Company Net Margins Return on Equity Return on Assets Opus Genetics-429.42% -283.28% -144.32% Semper Paratus Acquisition N/A N/A -934.56% SummarySemper Paratus Acquisition beats Opus Genetics on 6 of the 11 factors compared between the two stocks. Get Opus Genetics News Delivered to You Automatically Sign up to receive the latest news and ratings for IRD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IRD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IRD vs. The Competition Export to ExcelMetricOpus GeneticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$58.26M$2.84B$5.46B$8.92BDividend YieldN/A2.70%5.35%4.14%P/E Ratio-0.4720.8926.1519.64Price / Sales5.30281.81410.74112.88Price / CashN/A41.2925.7827.49Price / Book4.657.197.875.41Net Income-$57.53M-$55.05M$3.16B$248.99M7 Day Performance2.79%0.76%3.10%3.99%1 Month Performance-1.80%4.39%4.62%4.82%1 Year PerformanceN/A-0.74%31.74%17.00% Opus Genetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IRDOpus Genetics1.8051 of 5 stars$0.98-4.3%$7.33+650.9%N/A$58.26M$10.99M-0.4714News CoverageAnalyst ForecastTVGNSemper Paratus Acquisition4.2066 of 5 stars$1.16-3.3%$7.10+512.1%+71.5%$220.67MN/A0.003Positive NewsBTMDbiote3.3547 of 5 stars$4.01+1.3%$8.00+99.5%-43.8%$216.65M$197.19M6.57194Positive NewsINBXInhibrx Biosciences1.5225 of 5 stars$14.56-2.5%N/A+1.8%$216.12M$200K0.12166DSGNDesign Therapeutics1.3871 of 5 stars$3.90+4.3%$4.00+2.6%+6.6%$212.32MN/A-3.9440Positive NewsESPREsperion Therapeutics4.2776 of 5 stars$1.04-2.8%$7.00+573.1%-55.2%$212.07M$332.31M-1.30200Positive NewsNBTXNanobiotix2.4292 of 5 stars$4.45-0.5%$8.00+79.8%-7.8%$210.68M-$11.61M0.00100Gap DownMDWDMediWound1.8313 of 5 stars$18.99-0.5%$31.80+67.5%+24.1%$206.32M$20.22M-9.0980News CoverageCRDFCardiff Oncology1.6544 of 5 stars$3.16+1.9%$12.00+279.7%+41.9%$206.23M$680K-3.4320News CoverageAnalyst ForecastIMABI-Mab2.5706 of 5 stars$2.46-1.6%$5.50+123.6%+53.9%$204.15M$3.89M0.00380News CoverageAnalyst ForecastGap UpPRQRProQR Therapeutics1.941 of 5 stars$1.95+1.0%$8.00+310.3%+22.9%$203.06M$20.46M-5.57180News CoverageAnalyst Forecast Related Companies and Tools Related Companies Semper Paratus Acquisition Alternatives biote Alternatives Inhibrx Biosciences Alternatives Design Therapeutics Alternatives Esperion Therapeutics Alternatives Nanobiotix Alternatives MediWound Alternatives Cardiff Oncology Alternatives I-Mab Alternatives ProQR Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IRD) was last updated on 6/29/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Opus Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Opus Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
